EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

GSK-3484862 targets DNMT1 for degradation in cells

Qin Chen, Bigang Liu, Yang Zeng, Jee Won Hwang, Nan Dai, Ivan R Corrêa, Marcos R Estecio, Xing Zhang, Margarida A Santos, Taiping Chen, Xiaodong Cheng iD

NAR Cancer · 11.03.2023 · 5 (2)

DOI: 10.1093/narcan/zcad022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 17.05.2023. Verfasst von Qin Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX77030, USA. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Institutes of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maintenance of genomic methylation patterns at DNA replication forks by DNMT1 is the key to faithful mitotic inheritance. DNMT1 is often overexpressed in cancer cells and the DNA hypomethylating agents azacytidine and decitabine are currently used in the treatment of hematologic malignancies. However, the toxicity of these cytidine analogs and their ineffectiveness in treating solid tumors have limited wider clinical use. GSK-3484862 is a newly-developed, dicyanopyridine containing, non-nucleoside DNMT1-selective inhibitor with low cellular toxicity. Here, we show that GSK-3484862 targets DNMT1 for protein degradation in both cancer cell lines and murine embryonic stem cells (mESCs). DNMT1 depletion was rapid, taking effect within hours following GSK-3484862 treatment, leading to global hypomethylation. Inhibitor-induced DNMT1 degradation was proteasome-dependent, with no discernible loss of DNMT1 mRNA. In mESCs, GSK-3484862-induced Dnmt1 degradation requires the Dnmt1 accessory factor Uhrf1 and its E3 ubiquitin ligase activity. We also show that Dnmt1 depletion and DNA hypomethylation induced by the compound are reversible after its removal. Together, these results indicate that this DNMT1-selective degrader/inhibitor will be a valuable tool for dissecting coordinated events linking DNA methylation to gene expression and identifying downstream effectors that ultimately regulate cellular response to altered DNA methylation patterns in a tissue/cell-specific manner.

Autor:innen und Institutionen

  • Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX77030, USA.
  • Program in Genetics and Epigenetics, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX77030, USA.
  • New England Biolabs, Inc, Ipswich, MA 01938, USA.

ORCID-Profile: Xiaodong Cheng

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health
  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Chen, Q., Liu, B., Zeng, Y., Hwang, J. W., Dai, N., Corrêa, I. R., Estecio, M. R., Zhang, X., Santos, M. A., Chen, T., & Cheng, X. (2023). GSK-3484862 targets DNMT1 for degradation in cells. NAR Cancer, 5(2). https://doi.org/10.1093/narcan/zcad022

Vancouver

Chen Q, Liu B, Zeng Y, Hwang JW, Dai N, Corrêa IR, et al. GSK-3484862 targets DNMT1 for degradation in cells. NAR Cancer. 2023;5(2). doi:10.1093/narcan/zcad022

BibTeX
@article{Chen2023,
  author = {Chen, Qin and Liu, Bigang and Zeng, Yang and Hwang, Jee Won and Dai, Nan and Corrêa, Ivan R and Estecio, Marcos R and Zhang, Xing and Santos, Margarida A and Chen, Taiping and Cheng, Xiaodong},
  title = {GSK-3484862 targets DNMT1 for degradation in cells},
  journal = {NAR Cancer},
  year = {2023},
  volume = {5},
  number = {2},
  doi = {10.1093/narcan/zcad022}
}
Kostenlos starten →